KYTHERA Acquires Rights to ATX-101 Outside of the U.S. and Canada From Bayer Consumer Care

KYTHERA Acquires Rights to ATX-101 Outside of the U.S. and Canada From Bayer
Consumer Care

                  KYTHERA Now Holds Global Rights to ATX-101

               KYTHERA to Host Conference Call Today at 4:30 ET

CALABASAS, Calif., March 10, 2014 (GLOBE NEWSWIRE) -- KYTHERA
Biopharmaceuticals, Inc. (Nasdaq:KYTH) and Bayer Consumer Care today announced
that KYTHERA acquired all rights outside of the U.S. and Canada to ATX-101, a
proprietary formulation of a purified synthetic version of deoxycholic acid
currently in late-stage development for the reduction of submental fat (double
chin). In 2010, KYTHERA licensed the commercial rights to ATX-101 outside of
the U.S. and Canada to Bayer Consumer Care AG.

"We are very pleased to acquire all rights to ATX-101 outside the U.S. and
Canada, giving us full global rights to develop and commercialize ATX-101,"
said Keith Leonard, KYTHERA's president and CEO. "We appreciate Bayer's
investment in the ATX-101 global development program over the past four years.
During that time we strengthened our financial position and assembled a senior
executive team with global aesthetic development and commercialization
expertise. I am confident in our ability to maximize the long-term global
value of ATX-101. While our primary focus remains filing our U.S. New Drug
Application in the second quarter of 2014, we also plan to make multiple
ex-U.S. regulatory submissions in the next 12 months."

Under the new agreement, KYTHERA Holdings Ltd., a wholly-owned Bermuda
subsidiary of KYTHERA Biopharmaceuticals, Inc., acquired rights to develop and
commercialize ATX-101 outside the U.S. and Canada. Bayer will receive $33
million in KYTHERA common stock, plus a $51 million note, payable no later
than 2024. Bayer is also eligible to receive certain long-term sales milestone
payments on annual sales outside of the U.S. and Canada.

For the past six years, ATX-101 has been the focus of a global clinical
development program that has enrolled more than 2,500 patients worldwide, of
which more than 1,600 have been treated with ATX-101. In addition, positive
and consistent results from multiple Phase III trials were reported in the
U.S. and Europe, and will provide the basis for regulatory submissions for
approval of ATX-101. KYTHERA plans to file a New Drug Application (NDA) for
ATX-101 with the U.S. Food and Drug Administration (FDA) in the second quarter
of 2014. In addition, KYTHERA plans to make multiple ex-U.S. regulatory
submissions in the next 12 months. If approved, ATX-101 will be a
first-in-class submental contouring injectable drug.

Conference Call

KYTHERA will host an investor conference call and webcast March 10 at 4:30
p.m. (Eastern Time). To participate in the call, dial (877) 344-3890 (U.S. and
Canada) or (760) 666-3770 (international) using conference ID number 11342470.
To access the webcast, please visit the Investors section of KYTHERA's website
at www.kytherabiopharma.com.

The call will be available for replay via telephone starting March 10 at
approximately 5:30 pm ET, running through 11:59 p.m. ET on March 17. To listen
to the replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406
(international) using conference ID number 11342470. The archived webcast will
be available on KYTHERA's website for 14 days beginning approximately one hour
after the call has completed.

About KYTHERA Biopharmaceuticals, Inc.

KYTHERA Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of novel
prescription products for the aesthetic medicine market. KYTHERA's product
candidate, ATX-101, is currently in late-stage development for the reduction
of submental fat, which commonly presents as a double chin, and is a potential
first-in-class submental contouring injectable drug. KYTHERA also maintains an
active research interest in hair and fat biology, pigmentation modulation and
facial contouring.

Forward-Looking Statements

To the extent that statements contained in this press release are not
descriptions of historical facts regarding KYTHERA, they are forward-looking
statements reflecting the current beliefs and expectations of management made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, including the potential for ATX-101 to fulfill an unmet
global need, our confidence in our ability to maximize global value of
ATX-101; the potential for ATX-101 to be a first-in-class submental contouring
injectable drug; the timing of our U.S. NDA filing; the timing and number of
ex-U.S. regulatory filings; the use of data from Phase III trials in our
regulatory submissions; and our ability to repay the $51 million note. Such
forward-looking statements involve substantial risks and uncertainties that
could cause our clinical development programs, future results, performance, or
achievements to differ significantly from those expressed or implied by the
forward-looking statements.Such risks and uncertainties include, among
others, the uncertainties inherent in the regulatory approval process, our
substantial dependence on ATX-101 and other matters that could affect the
availability or commercial potential of our drug candidate. KYTHERA undertakes
no obligation to update or revise any forward-looking statements.For a
further description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking statements, as
well as risks relating to the business of the Company in general, see
KYTHERA's reports filed with the Securities and Exchange Commission, including
its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 and
our Annual Report on Form 10-K for the year ended December 31, 2012.

CONTACT: Investor Contact:
         Heather Rowe
         Associate Director, Investor Relations
         Tel: (818) 587-4559
         hrowe@kytherabiopharma.com

KYTHERA logo
 
Press spacebar to pause and continue. Press esc to stop.